ERS/ECDC statement: European Union standards for tuberculosis care, 2017 update

European Respiratory Journal

Volumn 51, Issue 5, 2018, Pages

  Migliori, Giovanni Battista ^w   Sotgiu, Giovanni ^a   Rosales Klintz, Senia ^x   Centis, Rosella ^w   D'Ambrosio, Lia ^b,w   Abubakar, Ibrahim ^c   Bothamley, Graham ^d   Caminero, Jose Antonio ^e,f   Cirillo, Daniela Maria ^g   Dara, Masoud ^h   De Vries, Gerard ⁱ   Aliberti, Stefano ^j   Dinh Xuan, Anh Tuan ^k   Duarte, Raquel ^l   Midulla, Fabio ^m   Solovic, Ivan ⁿ   Subotic, Dragan R ^o   Amicosante, Massimo ^p   Correia, Ana Maria ^q   Cirule, Andra ^r   Gualano, Gina ^s   Kunst, Heinke ^t   Palmieri, Fabrizio ^s   Riekstina, Vija ^r   Tiberi, Simon ^t,u   Verduin, Remi ^v   Van Der Werf, Marieke J ^x   more..

^a UNIVERSITY OF SASSARI   (Italy)

^b Public Health Consulting Group SAGL   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^e HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^f INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k Institut Cochin   (France)

^l University of Porto   (Portugal)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ CATHOLIC UNIVERSITY IN RU OMBEROK   (Slovakia)

^o Clinic of Cardiac Surgery   (Serbia)

^p UNIVERSITY OF ROME TOR VERGATA   (Italy)

^q Regional Health Directorate of North   (Portugal)

^r RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^s NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^t QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^u ROYAL LONDON HOSPITAL   (United Kingdom)

^v Verduin Public Health Consult   (Netherlands)

^w IRCCS   (Italy)

^x EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; BEDAQUILINE; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLOFAZIMINE; CYCLOSERINE; DELAMANID; DEXAMETHASONE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PREDNISONE; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; TERIZIDONE;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; COMORBIDITY; DISEASE TRANSMISSION; DRUG MEGADOSE; EUROPEAN UNION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; KIDNEY TUBERCULOSIS; LUNG TUBERCULOSIS; MEDICAL SOCIETY; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS MENINGITIS; TUBERCULOUS PERICARDITIS; TUBERCULOUS SPONDYLITIS; WHOLE GENOME SEQUENCING; PATIENT CARE; STANDARDS;

COMORBIDITY; EUROPEAN UNION; HUMANS; PATIENT CARE; PUBLIC HEALTH; SOCIETIES, MEDICAL; TUBERCULOSIS;

EID: 85048791093     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02678-2017     Document Type: Review

References (129)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2018-2016 data. Stockholm, European Centre for Disease Prevention and Control, 2018. Available from: https://ecdc.europa.eu/sites/portal/files/documents/ecdc-tuberculosis-surveillance-monitoringEurope-2018-19mar2018.pdf
2. Lonnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
3. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
4. van der Werf MJ, Kodmon C, Hollo V, et al. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. Euro Surveill 2014; 19: 20733.
5. van der Werf MJ, Kodmon C, Zucs P, et al. Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles. AIDS 2016; 30: 2845-2853.
6. van der Werf MJ, Sotgiu G, Dara M. Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances. Eur Respir J 2017; 50: 1701758.
7. van der Werf MJ, Erkens C, Gebhard A, et al. First joint meeting of three European tuberculosis networks. Euro Surveill 2013; 18: 20583.
8. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
9. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). 2nd edn. The Hague, Tuberculosis Coalition for Technical Assistance, 2009.
10. TB CARE I. International Standards for Tuberculosis Care. 3rd edn. The Hague, TB CARE, 2014.
11. Migliori GB, Sotgiu G, Blasi F, et al. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J 2011; 38: 493-495.
12. World Health Organization. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis. Geneva, World Health Organization, 2017.
13. van der Werf MJ, Sandgren A, D'Ambrosio L, et al. The European Union standards for tuberculosis care: do they need an update? Eur Respir J 2014; 43: 933-942.
14. Sotgiu G, Beer N, Aliberti S, et al. Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care. Eur Respir J 2016; 48: 1278-1281.
15. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
16. Drobniewski FA, Hoffner S, Rusch-Gerdes S, et al. Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J 2006; 28: 903-909.
17. World Health Organization Regional Office for Europe. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapid molecular diagnostic technologies. Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region. Copenhagen, WHO Regional Office for Europe, 2017.
18. European Centre for Disease Prevention and Control. Handbook on TB laboratory diagnostic methods for the European Union. Stockholm, ECDC, 2016.
19. Veen J, Migliori GB, Raviglione M, et al. Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. Eur Respir J 2011; 37: 950-959.
20. World Health Organization, European Respiratory Society. Framework towards tuberculosis elimination in low-incidence countries. Geneva, World Health Organization, 2014.
21. World Health Organization Regional Office for Europe. Roadmap to implement the tuberculosis action plan for the European Region 2016-2020. Towards ending tuberculosis and multidrug-resistant tuberculosis. Copenhagen, WHO Regional Office for Europe, 2016.
22. World Health Organization. Implementing the end TB strategy: the essentials. Geneva, World Health Organization, 2015.
23. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva, Word Health Organization, 2013.
24. World Health Organization. Implementing tuberculosis diagnostics. Policy framework. Geneva, World Health Organization, 2015.
25. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64: e1-e33.
26. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63: e147-e195.
27. Sotgiu G, Nahid P, Loddenkemper R, et al. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur Respir J 2016; 48: 963-971.
28. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. Geneva, World Health Organization, 2016.
29. Falzon D, Schunemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
30. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva, World Health Organization, 2017.
31. World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015.
32. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.
33. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008; 8: 15.
34. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010; 36: 925-949.
35. European Respiratory Society, European Lung Foundation. Lung Health in Europe Facts and Figures. Loddenkemper R, Gibson G, Sibille Y, eds. Sheffield, European Respiratory Society, 2003.
36. Schwoebel V, Lambregts CS, Moro ML, et al. European recommendations on surveillance of antituberculosis drug resistance. Euro Surveill 2000; 5: 104-106.
37. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, World Health Organization, 2010.
38. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers 2016; 2: 16076.
39. Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; 15: 1193-1202.
40. Kendall EA, Cohen T, Mitnick CD, et al. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis 2017; 56: 185-189.
41. Trajman A, Durovni B, Saraceni V, et al. High positive predictive value of Xpert in a low rifampicin resistance prevalence setting. Eur Respir J 2014; 44: 1711-1713.
42. Albert H, Nathavitharana RR, Isaacs C, et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016; 48: 516-525.
43. Chakravorty S, Simmons AM, Rowneki M, et al. The New Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 2017; 8: e00812-17.
44. Nathavitharana RR, Cudahy PG, Schumacher SG, et al. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J 2017; 49: 1601075.
45. Theron G, Peter J, Richardson M, et al. GenoType(R) MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2016; 9: CD010705.
46. Sehgal IS, Dhooria S, Aggarwal AN, et al. Diagnostic performance of Xpert MTB/RIF in tuberculous pleural effusion: systematic review and meta-analysis. J Clin Microbiol 2016; 54: 1133-1136.
47. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-1174.
48. Pai M, Nicol MP, Boehme CC. Tuberculosis diagnostics: state of the art and future directions. Microbiol Spectr 2016; 4: TBTB2-0019-2016.
49. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
50. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
51. Pankhurst LJ, Del Ojo Elias C, Votintseva AA, et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 2016; 4: 49-58.
52. Walker TM, Cruz ALG, Peto TE, et al. Tuberculosis is changing. Lancet Infect Dis 2017; 17: 359-361.
53. Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug-resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354.
54. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
55. National Instititute for Health and Care Excellence. Tuberculosis (NG33). London, NICE, 2016.
56. World Health Organization. Toman's tuberculosis. Case detection, treatment, and monitoring- questions and answers. Frieden T, ed. Geneva, World Health Organization, 2004.
57. Datta S, Shah L, Gilman RH, et al. Comparison of sputum collection methods for tuberculosis diagnosis: a systematic review and pairwise and network meta-analysis. Lancet Glob Health 2017; 5: e760-e771.
58. World Health Organization. Rapid Advice: Treatment of Tuberculosis in Children. Geneva, World Health Organization, 2010.
59. Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186: 953-964.
60. Schoch OD, Rieder P, Tueller C, et al. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med 2007; 175: 80-86.
61. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm, ECDC, 2011.
62. Sotgiu G, Tiberi S, D'Ambrosio L, et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016; 387: 2486-2487.
63. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
64. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
65. Petruccioli E, Scriba TJ, Petrone L, et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 2016; 48: 1751-1763.
66. Goletti D, Petruccioli E, Joosten SA, et al. Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep 2016; 8: 6568.
67. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd edn. Geneva, World Health Organization, 2014.
68. World Health Organization. Report of a WHO consultation on strengthening the active engagement of civil society organizations in the global TB prevention, care and control efforts. Geneva, World Health Organization, 2010. Report No.: WHO/HTM/TB/2010.15.
69. World Care Council. Patients' Charter for Tuberculosis Care. Viols en Laval, World Care Council, 2006.
70. Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
71. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000; 355: 1345-1350.
72. Mitnick CD, White RA, Lu C, et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J 2016; 48: 1160-1170.
73. Lange C, Duarte R, Frechet-Jachym M, et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in europe. Am J Respir Crit Care Med 2016; 194: 1029-1031.
74. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less, the new “Shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507.
75. van der Werf MJ, Hollo V, Kodmon C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.
76. van der Werf MJ, Kodmon C, Catchpole M, et al. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe. Eur Respir J 2017; 49: 1700463.
77. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
78. van Altena R, Akkerman OW, Alffenaar JC, et al. Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. Eur Respir J 2016; 48: 1800-1802.
79. Caminero JA, Piubello A, Scardigli A, et al. Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. Eur Respir J 2017; 50: 1700648.
80. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387.
81. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
82. Tadolini M, Garcia-Prats AJ, D'Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48: 938-943.
83. Aung KJ, Van Deun A, Declercq E, et al. Successful “9-month Bangladesh regimen” for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
84. Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-524.
85. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
86. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
87. Heldal E, van Deun A, Chiang CY, et al. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe. Eur Respir J 2017; 49: 1700228.
88. Javaid A, Ahmad N, Khan AH, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J 2017; 49: 1601967.
89. Van Deun A, Chiang CY. Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance. Eur Respir J 2017; 49: 1700223.
90. Dalcolmo M, Gayoso R, Sotgiu G, et al. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. Eur Respir J 2017; 49: 1602309.
91. Chee CBE, KhinMar KW, Sng L, et al. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Eur Respir J 2017; 50: 1700753.
92. Kendall EA, Fojo AT, Dowdy DW. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med 2017; 5: 191-199.
93. Sotgiu G, Migliori G. Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis. Lancet Respir Med 2017; 5: 159-161.
94. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
95. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.
96. World Health Organization. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation. Geneva, World Health Organization, 2015.
97. Halleux CM, Falzon D, Merle C, et al. The WHO global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis. Eur Respir J 2018; 51: 1701643.
98. Gunther G, Lange C, Alexandru S, et al. Treatment outcomes in multidrug-resistant tuberculosis. N Engl J Med 2016; 375: 1103-1105.
99. World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva, World Health Organization, 2012.
100. European Centre for Disease Prevention and Control. Management of contacts of MDRTB and XDR TB patients. Stockholm, ECDC, 2012.
101. Zenner D, Beer N, Harris RJ, et al. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med 2017; 167: 248-255.
102. Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur Respir J 2011; 37: 1269-1282.
103. Luzzati R, Migliori G, Zignol M, et al. Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: an out-patient outbreak from a smear-positive healthcare worker. Eur Respir J 2017; 50: 1701414.
104. European Centre for Disease Prevention and Control. Guidance on tuberculosis control in vulnerable and hard-to-reach populations. Stockholm: ECDC, 2016.
105. Dara M, de Colombani P, Petrova-Benedict R, et al. Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J 2012; 40: 1081-1090.
106. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711.
107. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; CD000171.
108. European Centre for Disease Prevention and Control. Investigation and control of tuberculosis incidents affecting children in congregate settings. Stockholm, ECDC, 2013.
109. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
110. Lange C, Rieder HL. Intention to test is intention to treat. Am J Respir Crit Care Med 2011; 183: 3-4.
111. World Health Organization. WHO policy on TB infection control in health - care facilities, congregate settings and households. Geneva, World Health Organization, 2009.
112. Sotgiu G, D'Ambrosio L, Centis R, et al. TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel? Eur Respir J 2011; 38: 1221-1223.
113. Matteelli A, Centis R, D'Ambrosio L, et al. WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Rev Respir Med 2016; 10: 991-1002.
114. Turusbekova N, Ljungqvist I, Davidaviciene E, et al. Tuberculosis infection control in health facilities in Lithuania: lessons learnt from a capacity support project. Public Health Action 2016; 6: 22-24.
115. Turusbekova N, Popa C, Dragos M, et al. Strengthening TB infection control in specialized health facilities in Romania-using a participatory approach. Public Health 2016; 131: 75-81.
116. Schmidt BM. Tuberculosis interventions to prevent transmission of infection in health care workers: a systematic review. Thesis, Cape Town, University of Cape Town, 2014.
117. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54: 1-141.
118. Acuña-Villaorduña C, Jones-Lopez E, Fregona G, et al. Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease. Eur Respir J 2018; 51: 1701578.
119. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
120. Mor Z, Migliori GB, Althomsons SP, et al. Comparison of tuberculosis surveillance systems in low-incidence industrialised countries. Eur Respir J 2008; 32: 1616-1624.
121. Uplekar M, Atre S, Wells WA, et al. Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practices. Eur Respir J 2016; 48: 1571-1581.
122. Heldal E, Kuyvenhoven JV, Wares F, et al. Diagnosis and treatment of tuberculosis in undocumented migrants in low- or intermediate-incidence countries. Int J Tuberc Lung Dis 2008; 12: 878-888.
123. Williams G, Alarcon E, Jittimanee S, et al. Guidance for the implementation of best practice for the care of patients with tuberculosis. Int J Tuberc Lung Dis 2008; 12: 236-240.
124. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014; 44: 543-546.
125. Al Yaquobi F, Al-Abri S, Al-Abri B, et al. Tuberculosis elimination: a dream or reality? The case of Oman. Eur Respir J 2018; 51: 1702027.
126. World Health Organization. Framework for the engagement of all health care providers in the management of drug resistant tuberculosis. Geneva, World Health Organization, 2015.
127. World Health Organization. Public-private mix for drug-resistant tuberculosis management: a situation assessment tool to engage all relevant care providers in drug-resistant tuberculosis (DR-TB) management at country level. Geneva, World Health Organization, 2015.
128. World Health Organization. Public-Private Mix for TB care and control. A tool for national situation assessment. Geneva, World Health Organization, 2007.
129. World Health Organization. Ethics guidance for the implementation of the End TB strategy. Geneva, World Health Organization, 2017.